Immunohistochemical evaluation of the microvascular density through the expression of TGF-β (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas

Neuropathology

Volumn 28, Issue 1, 2008, Pages 17-23

  Corteze Netto, Gabriel ^a,c   Birlem Bleil, Cristina ^a   Hilbig, Arlete ^a,b   Barbosa Coutinho, Lígia Maria ^a,b  

^a Fundação Faculdade Federal de Ciências Médicas de Porto Alegre   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c NONE   (Brazil)

Author keywords

CD 34; CD105; Microvascular density; Oligodendrogliomas; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; CANCER ANTIBODY; CD34 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; EVALUATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OLIGODENDROGLIOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD34; BRAIN NEOPLASMS; CHILD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OLIGODENDROGLIOMA; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37549020713     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2007.00825.x     Document Type: Article

References (49)

1. Tola MR, Casseta I, Granieri E et al. Intracranial gliomas Ferrara. Acta Neurol Scand 1994 90 : 312 317.
2. Lantos PL. Tumours of the nervous system. In : Graham DI, Lantos PL, eds. Greenfieldd's Neuropathology, Vol. 2, 7th edn. London : Arnold, 2002 810 821.
3. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of oligodendroglial neoplasms. J Neurooncol 2002 58 : 237 253.
4. Balmaceda CM, Fine RL. Gliomas. In : Rowland LP, ed. Merrit Tratado de Neurologia, 10th edn. Rio de Janeiro : Guanabara Koogan, 2002 273 289.
5. Vaquero J, Zurita M, Coca S et al. Prognostic significance of clinical and angiogenesis-related factors in low-grade oligodendrogliomas. Surg Neurol 2000 54 : 229 234.
6. Varlet P, Guillamo JS, Nataf F et al. Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival. Neuropathol Appl Neurobiol 2000 26 : 379 389.
7. Chaudhry IH, O'Donovan DG, Brenchley PE et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001 39 : 409 415.
8. Pietsch T, Valter MM, Wolf HK et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol (Berl) 1997 93 : 109 117.
9. Christov C, Adle-Biassette H, Le Guerinel C et al. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 1998 24 : 29 35.
10. Schiffer D, Bosone I, Dutto A et al. The prognostic role of vessel productive changes and vessel density in oligodendroglioma. Neurooncol 1999 44 : 99 107.
11. Chan AS, Leung SY, Wong MP et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998 22 : 816 826.
12. Vaquero J, Zurita M, Morales C et al. Prognostic significance of tumor-enhancement and angiogenesis in oligodendroglioma. Acta Neurol Scand 2002 106 : 19 23.
13. Fox SB, Harris AL. Markers of tumor angiogenesis: clinical applicatios in prognosis and anti-angiogenic therapy. Invest New Drugs 1997 15 : 15 28.
14. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000 407 : 249 257.
15. Folkman J. What is the evidence that the tumors are angiogenesis dependent? J Natl Cancer Inst 1990 82 : 4 6.
16. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002 29 : 15 17.
17. Folkman J. Angiogenesis and tumor growth. N Engl J Med 1996 334 : 921.
18. Ferrara N. Role of vascular endothelial growth factor in physiology and pathology angiogenesis: therapeutic implication. Semin Oncol 2002 29 : 10 14.
19. Herlyn M. Endothelial cells as targets for tumor therapy. J Immunother 1999 22 : 185.
20. D'more P. Tissue repair: cellular growth, fibroses and wound healing. In Contran RS, Kumar V, Collins T, eds. Robbins-Pathologic Basis of Disease, 6th edn. Philadelphia : W.B. Saunders Company, 1999 89 112.
21. Le Querrec A, Duval D, Toblem G. Tumor angiogenesis. Baillieres Clin Haematol 1993 6 : 711 730.
22. Folkman J et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989 339 : 58 61.
23. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 285 : 82 86.
24. Poon RT-P, Fan S-T, Wong J. Clinical Implications of circulanting angiogenic factors in cancer patients. J Clin Oncol 2001 46 : 1207 1225.
25. Fonsatti E, Altomonte M, Nicotra MR et al. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003 22 : 6557 6563.
26. Dales JP, Garcia S, Carpentier S et al. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol 2004 35 : 176 183.
27. Yancopoulos GD, Davis S, Gale NW et al. Vascular-specific growth factors and blood vessel formation. Nature 2000 407 : 242 248.
28. Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 1998 49 : 189 195.
29. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004 25 : 558 611.
30. Vidal S, Kovacs K, Lloyd RV et al. Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome. Cancer 2002 94 : 738 745.
31. Hansen S, Grabau DA, Sorensen FB et al. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 2000 6 : 139 146.
32. Carmiliet P. Maniplating angiogenesis in medicine. J Int Med 2004 255 : 538 561.
33. Vermeulen PB, Gasparini G, Fox SB et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996 32A (14 2474 2484.
34. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med 2004 2 (1 18.
35. Wikstrom P, Lissbrant IF, Stattin P et al. Endoglin [CD105] is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002 51 : 268 275.
36. Duff SE, Li C. CD 105 is important for angiogenesis: evidence and potential applications. FASEB J 2003 17 : 984 992.
37. Tanaka F, Otake Y, Yanagihara K et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001 7 : 3410 3415.
38. Ho JM, Poon RT, Sun CK et al. Clinicopathological and prognostic implications of endoglin (CD 105) expression in hepatocellular carcinoma and its adjacent non-tumours liver. World J Gastroenterol 2005 11 : 176 181.
39. Blobe GC, Schielmann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000 348 : 1350 1358.
40. Gold LI, Parekh TV. Loss of growth regulation by transforming growth factor-beta (TGF-beta) in human cancers: studies on endometrial carcinoma. Semin Reprod Med 1999 17 : 73 92.
41. Hentges S, Sarkar DK. Transforming growth factor-β regulation of estradiol-induced prolactinomas. Front Neuroendocrinol 2001 22 : 185.
42. Cheifetz S, Bellon T, Cales C et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992 267 : 19027 19030.
43. Seon BK, Matsuno F, Haruta Y et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endotelial cells of tumor vasculature with antihuman endoglin immumotoxin. Clin Cancer Res 1997 3 : 1031 1044.
44. Li C. CD 105 antagonizes the inhibitory signaling of transforming growth factor β1 on human vascular endothelial cells. FASEB J 2000 14 : 55 64.
45. Vermeulen PB, Gasparini G, Fox SB et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002 38 : 1564 1579.
46. Brem S. Angiogenesis and câncer control: from concepts to therapeutic trial. Cancer Control 1999 6 : 436 458.
47. Plate KH, Breier G, Weich HA et al. Vascular endothelial growth factor is a potencial tumor angiogenic factor in human gliomas in vivo. Nature 1992 359 : 845 848.
48. Aronsson DE, Muhr C. Quantification of sensitivity of endothelial cell markers for the astrocytoma and oligodendrogliomas tumours. Anticancer Res 2002 22 : 343 346.
49. Yao Y, Kubota T, Takeuchi H et al. Prognostic signicance of nicrovessel density determined by an anti-CD 105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD 31 monoclonal antibody. Neuropathology 2005 25 : 201 206.